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Uncovering the multifaceted roles played by neutrophils in
allogeneic hematopoietic stem cell transplantation
Cristina Tecchio1 and Marco Antonio Cassatella2
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a life-saving procedure used for the treatment of selected
hematological malignancies, inborn errors of metabolism, and bone marrow failures. The role of neutrophils in alloHSCT has been
traditionally evaluated only in the context of their ability to act as a first line of defense against infection. However, recent evidence
has highlighted neutrophils as key effectors of innate and adaptive immune responses through a wide array of newly discovered
functions. Accordingly, neutrophils are emerging as highly versatile cells that are able to acquire different, often opposite,
functional capacities depending on the microenvironment and their differentiation status. Herein, we review the current knowledge
on the multiple functions that neutrophils exhibit through the different stages of alloHSCT, from the hematopoietic stem cell (HSC)
mobilization in the donor to the immunological reconstitution that occurs in the recipient following HSC infusion. We also discuss
the influence exerted on neutrophils by the immunosuppressive drugs delivered in the course of alloHSCT as part of graft-versus-
host disease (GVHD) prophylaxis. Finally, the potential involvement of neutrophils in alloHSCT-related complications, such as
transplant-associated thrombotic microangiopathy (TA-TMA), acute and chronic GVHD, and cytomegalovirus (CMV) reactivation, is
also discussed. Based on the data reviewed herein, the role played by neutrophils in alloHSCT is far greater than a simple
antimicrobial role. However, much remains to be investigated in terms of the potential functions that neutrophils might exert
during a highly complex procedure such as alloHSCT.
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INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (alloHSCT) has
become a well-established life-saving procedure for selected
patients with hematological malignancies, inborn errors of
metabolism, or bone marrow (BM) failure syndromes.1 Briefly,
alloHSCT consists of transferring hematopoietic stem cells (HSCs)
from either a human leukocyte antigen (HLA)-identical sibling, an
HLA-matched unrelated donor, or even an alternative donor
[haploidentical-related, mismatched-unrelated, cord blood (CB)] to
a patient who has been prepared with a conditioning regimen.2
Infusion of HSCs is followed by a pre-engraftment phase, which is
characterized by a pancytopenia that lasts ~10–20 days, depend-
ing on the HSC source, donor type, conditioning regimen,
eventual granulocyte-colony-stimulating factor (G-CSF)-adminis-
tration, graft-versus-host disease (GVHD)-prophylaxis regimen, or
concurrent infectious/noninfectious complications.3,4 Engraft-
ment, a crucial phase of alloHSCT, is traditionally defined as the
first of three consecutive days during which the patient shows an
absolute neutrophil count higher than 0.5 × 109/l, along with
sustained platelet (>20 × 109/l) and hemoglobin levels (>80 g/l),
and does not require transfusion.4 After the engraftment, the
donor-derived immune system undergoes a reconstitution phase
consisting of a progressive acquisition of competences that relies
on the recovery of innate immunity cells during the first weeks,
and of adaptive immune cells in the subsequent months.3,5–7
Neutrophils are therefore among the first cells to reconstitute,
accounting for almost all peripheral blood cells in the first weeks
after alloHSCT.3 The other cells present during this period are
monocytes, natural killer (NK) cells, dendritic cells (DCs), and
residual T cells infused with the graft product and undergoing
peripheral expansion3,7. In patients affected by hematological
malignancies, alloHSCT effectiveness also relies on tumor eradica-
tion, which depends on both the conditioning regimen and,
mostly, graft-versus-tumor (GVT) effects mediated by donor-
derived T cells.2,8,9 Notably, alloHSCT is characterized by several
variables, including (1) the intensity of the conditioning regimen
(i.e., myeloablative versus reduced-intensity versus nonmyeloa-
blative); (2) the HSC source [i.e., BM versus mobilized peripheral
blood versus CB]; and (3) the type of immunosuppressive regimen
[i.e., cyclosporine (CSA) or tacrolimus with a short methotrexate
course, CSA and mycophenolate mofetil, eventual anti-thymocyte
globulins (ATG), and post-alloHSCT cyclophosphamide].10
Neutrophils are no longer viewed as involved only in primary
defense against infections.11 Recent discoveries of their multi-
faceted activities (mostly shown in Fig. 1) have in fact made it clear
that they also function as key effectors not only in the innate and
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adaptive immune responses but also in many unexpected
physiopathological processes, such as angiogenesis,12 immune-
mediated diseases,13 and cancer.14 In addition, it has been recently
demonstrated that, among the multiple functions exerted,
neutrophils are also able to engage in crosstalk with other
leukocytes,15 to migrate into lymph nodes (LNs)16 and even to
function as antigen-presenting cells (APCs).17 Neutrophils are also
emerging as highly versatile cells, being able to acquire different,
often opposite, functional capacities, depending on the physiolo-
gical or pathological context and on their differentiation/activation
status.18 Accordingly, different heterogeneous populations of
mature or immature neutrophils displaying distinct functions have
recently been identified, characterized, and named, even though
no general consensus exists on whether they unequivocally
represent definitive populations.18–20 Figure 2 schematizes the
current knowledge on the heterogeneity of neutrophils on the
basis of their function and intrinsic density. In fact, besides the
phenotype, one of the most often used criteria to distinguish
neutrophil populations consists of defining their ability to exert
either immunosuppressive actions (i.e., inhibition of the prolifera-
tion, or the production of IFN-γ, by activated T cells)21 or to display
enhanced proinflammatory functions [i.e., increased capacity to
produce proinflammatory cytokines and/or to release neutrophil
extracellular traps (NETs)].22 Cell density properties are uncovered
by centrifuging blood or other biological samples over commercial
gradients (for instance, Ficoll). Accordingly, mature neutrophils
from healthy donors (HDs) are often named “normal-density
neutrophils” (NDNs) and represent the cells that sediment as a
Fig. 1 Biologic activities of neutrophils that have been discovered in recent decades
Fig. 2 Heterogeneity of neutrophils. After centrifugation of blood from healthy donors over a density gradient, granulocytes typically
sediment on top of the erythrocyte layer, while mononuclear cells (i.e., PBMCs) sediment at the interface between the density gradient layer
and the plasma. Granulocytes include a homogeneous population of resting mature CD10+ neutrophils (conventionally called “normal-
density” neutrophils, NDNs) and a variable percentage of eosinophils (not shown).18 However, density gradient centrifugation of blood from
both patients with diseases and healthy donors may lead to the detection of heterogeneous populations of “low-density” neutrophils (LDNs)
within PBMCs under selected physiological conditions or in response to G-CSF stimulation. LDNs may include activated mature CD10+
neutrophils and immature CD10− neutrophils (mostly band cells and metamyelocytes, although a few myelocytes and promyelocytes may be
present) at different ratios.18,29,30 LDNs may manifest either immunosuppressive or proinflammatory properties.18,20 Immunosuppressive
CD66b+/CD15+ LDNs, also known as polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), are found in patients with, for
instance, cancer,29,31–36 infections,25,37 or graft-versus-host disease (GVHD),43,44 as well as in pregnant women38,39 and in G-CSF-treated
donors.30,40–42 Proinflammatory CD66b+/CD15+ LDNs, also known as low-density granulocytes (LDGs), are instead found in patients with
autoimmune diseases, such as systemic lupus erythematosus.22 Similarly, in some inflammatory/pathological settings, CD10+ NDNs present in
the granulocyte fraction may also display immunosuppressive18 rather than proinflammatory properties.18 To date, no specific markers have
been identified in the various neutrophil populations, which basically express the same phenotype present in NDNs (i.e., HLA-DR-/CD11b+/
CD14−/CD15+/CD33dim)
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white cell layer over the erythrocytes (Fig. 2). Patient NDNs may
become activated in vivo and in turn acquire immunomodulatory
functions that may be either immunosuppressive23–25 or proin-
flammatory/immunoactivating,26 depending on the disease.22,27,28
Populations of circulating neutrophils from patients may display a
lower density than NDNs as a result of intrinsic or external factors
(such as their immaturity or their in vivo activation, respectively),
which may lead them to localize within peripheral blood mono-
nuclear cells (PBMCs) after density gradient centrifugation. These
neutrophils are consequently named low-density neutrophils
(LDNs) (Fig. 2) and usually consist of a mixture of mature and
immature neutrophils.18,29,30 LDNs may also display distinct
immunomodulatory properties, depending on the disease or other
context. For instance, LDNs are highly proinflammatory in patients
with autoimmune diseases, in which they are also known as low-
density granulocytes (LDGs) (Fig. 2).22 By contrast, in patients with
cancer29,31–36 or infections,25,37 in women during pregnancy,38,39
and in HDs administered with G-CSF30,40–42 or in alloHSCT (as
described below),43,44 LDNs are immunosuppressive and are
conventionally called polymorphonuclear myeloid-derived sup-
pressive cells (PMN-MDSCs) or granulocytic MDSCs (G-MDSCs).
In virtue of accumulating evidence of the plasticity of neutrophils
and their ability to influence adaptive immunity,11,18 it is quite
surprising that neutrophils have been largely overlooked in the
context of alloHSCT. Herein, we review the most relevant studies
centered on the features, functions and roles played by human
neutrophils in alloHSCT, in both the donor [during peripheral blood
hematopoietic stem cell (PBSC) mobilization] and the recipient
(throughout the different phases of alloHSCT). The contribution of
neutrophils to alloHSCT-related complications will also be reviewed.
Studies from mouse models involving neutrophils and supporting
and/or reproducing alloHSCT-associated clinical or pathological
conditions will also be mentioned. While the issue of neutrophil
features and functions in alloHSCT is of utmost interest, some
caveats and problems should be taken into account. For instance,
with regard to in vivo experiments, attention should be paid to the
fact that preclinical models are always only partially representative
of the complexity of the alloHSCT procedure, especially in terms of
conditioning, immunosuppressive prophylactic treatment, and
concomitant drug administration.45 On the other hand, neutrophils
isolated from human peripheral blood or mouse BM for in vitro
studies are, according to the literature, not always purified at very
high levels (<97%); they are therefore often contaminated by
mononuclear cells, which may produce confounding results,
especially in terms of gene expression and cytokine release.46
Similarly, neutrophils must be carefully and rapidly processed in
lipopolysaccharide (LPS)-free medium and reagents to avoid results
from nonspecifically activated cells in in vitro experiments. Finally,
with respect to ex vivo studies, it is worth noting that alloHSCT
patient cohorts are usually not very homogenous, as they may differ
in terms of intensity of conditioning, HSC source, donor type,
concomitant comorbidities, and especially immunosuppressive
treatment. As a consequence, a reliable generalization of the results
observed in ex vivo studies, which include heterogeneous patient
populations, could be questionable in some ways. Given these limits,
the reader will notice that the literature on alloHSCT, unlike that
from other clinical settings, has only partially covered the biology of
neutrophils and leaves many related questions unanswered. In any
case, the information herein revised allows us to conclude that, in
alloHSCT, neutrophil functions far exceed those of simple phago-
cytes involved solely in antimicrobial activities.
FUNCTIONS AND HETEROGENEITY OF NEUTROPHILS DURING,
AND AFTER, G-CSF-INDUCED PBSC MOBILIZATION IN
HEALTHY DONORS
PBSCs currently represent the most commonly used HSC source
for adult alloHSCT.47 These cells are collected by apheresis from
the peripheral blood of HDs who have been previously
administered recombinant G-CSF for 4–5 days (hereafter, GDs).48
The term “mobilization” refers to the procedure that favors a G-
CSF-induced forced egression of HSCs from the BM into peripheral
blood as PBSCs before their harvest by apheresis into apheretic
graft products.48 Obviously, even though administered for HSC-
mobilizing purposes, G-CSF necessarily also impacts the activation
status and functions of neutrophils and their precursors. As
described below, two aspects of GD neutrophils have been the
focus of investigation by researchers: (1) the role of BM
neutrophils as mediators of PBSC mobilization during G-CSF
administration and (2) the heterogeneity and functions of
peripheral blood neutrophils at the end of the G-CSF-mobilizing
treatment period and in the apheresis product.
Role of BM neutrophils as mediators of PBSC mobilization during
G-CSF administration
As extensively reviewed by Tay et al.49 conflicting data are present
in the literature concerning the participation of neutrophils in G-
CSF-induced PBSC mobilization. In fact, it has been shown that G-
CSF does not directly act on HSCs (except for inducing their
expansion in BM, though with reduced self-renewal capacity50 and
survival under stressful conditions51) but rather functions indir-
ectly through other BM-resident cells expressing G-CSF
receptors.52,53 Accordingly, based on studies regarding PBSC
mobilization in HDs and mouse models, neutrophils were initially
indicated as hematopoietic intermediates of G-CSF. In this context,
neutrophil-derived serine proteases were found to cleave and
inactivate adhesion molecules and chemokines [respectively,
vascular cell adhesion molecule-1 (VCAM-1)52,54 and C-X-C motif
chemokine ligand 12 (CXCL12)55] that, under steady state, retain
HSCs in the BM niche (Fig. 3, mechanism 1). Consistently, BM
specimens from G-CSF-mobilized mice were characterized by a
sharp increase in mature neutrophils and their precursors54 and a
loss of VCAM-1 expression in stromal cells indicated by IHC
analysis.52,54 In vitro, extracellular BM fluids from the same mice
were found to cleave VCAM-1 similarly to supernatants from
human peripheral blood neutrophils, further indicating neutrophil
elastase (NE) and cathepsin G (CG) as the main serine proteases
involved in G-CSF-induced HSC mobilization.52,54 In keeping with
the aforementioned data, serum levels of soluble VCAM-1 and NE
were increased in G-CSF-mobilized patients.52 G-CSF-induced HSC
mobilization was also found to be associated with neutrophil-
mediated cleavage of the N-terminus of CXCR4 (namely, the
receptor for CXCL12) in both human and murine HSCs, either
resident in BM or mobilized in peripheral blood55 (Fig. 3,
mechanism 2). The concentration of CXCL12 in the BM of
mobilized HDs and mice was reported to decrease concomitant
with the accumulation of neutrophil-derived serine proteases.55,56
The latter enzymes were also reported to cleave the tyrosine
kinase C-KIT, namely, the stem cell factor (SCF) receptor, in murine
HSCs57 (Fig. 3, mechanism 2). Moreover, murine neutrophils,
expanded in BM upon G-CSF administration, were found to induce
apoptosis of mesenchymal stromal cells (MSCs) and osteoblasts
via the production of reactive oxygen species (ROS)58 (Fig. 3,
mechanism 3). As a consequence, the expression of CXCL12, SCF,
and VCAM-1, all molecules essential for HSC retention in the BM
endosteal niche, was found to drastically decrease.58 Overall, the
studies reported above point to a crucial role of G-CSF-stimulated
neutrophils (and their precursors) in favoring the egress of HSCs
from the BM niche through the release of serine proteases or ROS.
However, the putative central role of neutrophils in G-CSF-induced
PBSC mobilization has been questioned by other studies. In fact,
mice partially lacking the expression of NE, CG, or dipeptidyl
peptidase-I were shown to mobilize HSCs in response to G-CSF to
the same degree as wild-type mice.59 More recent evidence seems
to restrain the role of neutrophils in HSC mobilization, in turn
indicating that their protease release is only one of the multiple
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events that follow the G-CSF-induced shutdown of the endosteal
niche.60 Although G-CSF administration currently represents the
standard approved regimen for PBSC mobilization in HDs,61
research to identify alternative mobilizing agents is ongoing. For
instance, although still under investigational use in HDs,
AMD3100/plerixafor (which acts by inhibiting CXCR4 expressed
by HSCs), administered either alone62,63 or in combination with G-
CSF,64 represents an effective, direct HSC-mobilizing agent that
does not require neutrophil involvement. Moreover, based on
data from humans and murine models, plerixafor controls the
trafficking of neutrophils by inducing their demargination from
the lungs and blocking their homing to the BM65 or, alternatively,
by favoring their egress from the BM.66 Finally, combined
mobilization strategies targeting either very late antigen-4
(VLA4, an adhesion molecule that contributes to the retention of
HSCs in the BM niche) or CXCR2 (expressed by stromal cells and
neutrophils) have been explored at the preclinical level in mouse
models.67 In this context, neutrophils have been hypothesized to
boost the VLA4 agonist-induced mobilization of HSCs through the
release of proteases.67 In addition, upon stimulation with CXCR2
agonists, neutrophils could also favor the egress of HSCs from the
BM niche through interplay with endothelial cells.67
Heterogeneity and functions of peripheral blood neutrophils at
the end of the G-CSF-mobilizing treatment and in the apheresis
product
Ex vivo studies analyzing the phenotype and functions of
peripheral neutrophils following G-CSF administration for mobi-
lization purposes are relatively rare. This is due not only to the
prevalent interest of both researchers and clinicians in the yield
and quality of HSCs to be transplanted but also to a long-standing
view of neutrophils as short-lived cells, simply contaminants of the
apheresis graft products. Nonetheless, important data have
recently emerged on the immunomodulatory properties acquired
by peripheral human or mouse neutrophils following G-CSF-
induced PBSC mobilization. In fact, neutrophils from GDs have
been found to display a number of features distinguishing them
from those of HDs, other than appearing as heterogeneous
populations of both immature and mature activated cells with
distinctive characteristics68 (Fig. 4).
As already mentioned, studies carried out in cancer patients
originally showed that LDNs/PMN-MDSCs correlate in vivo with
reduced T-cell receptor ζ chain expression and ex vivo with
decreased production of cytokines such as interferon-γ (IFN-γ),
interleukin-4 (IL-4), tumor necrosis factor-α (TNF-α), and IL-2 by
phorbol-myristate acetate (PMA)- and ionomycin-stimulated
T cells.28 Interestingly, neutrophils with similar properties were also
described by Vasconcelos et al.40 in the peripheral blood of GDs
(Fig. 4). Accordingly, T-cell function, determined by IFN-γ and IL-4
production upon 4 h of treatment with PMA or ionomycin, was
significantly reduced in apheresis products from GDs compared to
BM and peripheral blood from HDs.40 Furthermore, a detailed
morphological analysis revealed that the mononuclear fraction of
the apheresis products was mainly composed of neutrophils (i.e.,
LDNs/PMN-MDSCs), whose death after 48 h of in vitro culture was
accompanied by a restoration of IFN-γ production by T cells.40 Later,
Luyckx et al.41 identified in unfractionated peripheral blood sampled
from GDs (Fig. 4) a population of mature SSChiCD33intCD14lowCD15+
neutrophils able to negatively regulate the alloreactivity of T cells
in vitro. Marini et al.30 further investigated the characteristics of
immunosuppressive neutrophils in terms of phenotypes and
functions in a study comparing peripheral blood NDNs and LDNs
from GDs versus NDNs from HDs. Based on CD10 expression as a
marker of mature neutrophils, both NDNs and LDNs were found to
contain a heterogeneous population composed of CD66b+CD10−
immature neutrophils and CD66b+CD10+ mature neutrophils30
(Fig. 4). Importantly, while CD66b+CD10− LDNs were found to
display immunostimulating functions, CD66b+CD10+ neutrophils
resulted in immunosuppressive functions30 (Fig. 4). Moreover,
Fig. 4 Graphic overview of the neutrophil populations isolated from
the peripheral blood of G-CSF-treated healthy donors, as well as
from their apheretic graft products (PBSCs). Data are extrapolated
from the literature. PB peripheral blood, PBSCs peripheral blood
stem cells. Neutrophil populations are CD66b+/CD15+ (T-suppres-
sive) LDNs40 (immunophenotype inferred from morphological data);
CD66b+ (NK-suppressive) LDNs;42 CD10+ (T-suppressive) LDNs;30
CD10+ (T-suppressive) NDNs;30 total/unfractionated CD15+ (T-
suppressive) neutrophils;41 and CD10−(T-activating) LDNs30
Fig. 3 Graphic representation of the proposed mechanisms
whereby neutrophils mediate peripheral blood hematopoietic stem
cell (PBSC) mobilization under G-CSF treatment. The depicted
mechanisms are as follows: 1 release of serine proteases, which in
turn cleave and inactivate adhesion molecules (i.e., VCAM-1) and
chemokines (i.e., CXCL12) expressed by stromal cells, retaining HSCs
in the BM niche;52,54,56 2 release of proteases that cleave CXCR4 (the
CXCL12 chemokine receptor) and C-KIT (the SCF receptor) on
HSCs;55,57 and 3 production of ROS, which in turn induce apoptosis
of MSCs and OBs and lead to the loss of CXCL12, SCF, and VCAM-1,
which are crucial for HSC retention in the BM niche.58 HSCs
hematopoietic stem cells, MSCs mesenchymal stromal cells, OBs
osteoblasts, VCAM-1 vascular cell adhesion molecule-1, CXCL12 C-X-
C motif chemokine ligand 12, CXCR4 C-X-C chemokine receptor 4, C-
KIT tyrosine kinase receptor C-KIT, ROS reactive oxygen species, SCF
stem cell factor
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CD66b+CD10+ neutrophils isolated by sorting from LDNs, NDNs, or
whole blood of GDs were found to inhibit CD3/CD28-induced
proliferation of and IFN-γ production by T cells in vitro via CD18-
mediated contact-dependent arginase 1 (Arg-1) release.30 As
expected, CD66b+CD10+ neutrophils isolated from NDNs of HDs
were not effective in modulating any T-cell function.30 In addition,
CD66b+CD10+ cells from GDs displayed an activated phenotype
that was characterized by lower CD16 and higher CD54/ICAM-1,
CD11c, and CD35 expression than was observed in CD66b+CD10+
neutrophils from unstimulated HDs.30 Although CD10 itself is known
to be an activation marker,69,70 the lack of T-cell suppressive
activities by CD10+ neutrophils from HDs suggests that in vivo G-
CSF induces complex cell reprogramming rather than a general
activation status. Interestingly, NDNs from HDs were found not to
acquire any immunosuppressive functions upon treatment with G-
CSF in in vitro experiments.30 Taken together, the data provided by
Marini et al.30 indicate that the immunosuppressive properties of
CD66+CD10+ mature neutrophils from GDs are strictly dependent
on in vivo exposure to G-CSF and eventually on other G-CSF-
induced factors, such as IL-6, IL-10, granulocyte-macrophage colony-
stimulating factor (GM-CSF), transforming growth factor-β (TGF-β),
and prostaglandin-E2 (PGE2), which are known to induce PMN-MDSC
differentiation.19 However, according to the same authors, the
immunosuppressive properties of CD66+CD10+ mature neutrophils
from GDs are not necessarily associated with their sedimentation
into the low-density fraction of the gradient.30 More recently,
Tumino et al.42 have identified in αβT-cell- and B cell-depleted
apheresis products from G-CSF mobilized haploidentical donors
(Fig. 4) a highly enriched population of PMN-MDSCs (i.e., low-density
CD45+Lin−HLA-DR−/lowCD33+CD11b+CD14−CD66b+ cells) able to
exert sharp inhibition of the cytotoxic activity of autologous NK cells
against recipient leukemic blasts in vitro. Based on these findings,
the authors hypothesized that the PMN-MDSCs in αβT-cell- and B
cell-depleted apheresis products might inhibit the graft-versus-
leukemia activity exerted in the recipient by the coinfused mature
NK cells.42 Interestingly, the immunosuppressive activity of the same
PMN-MDSCs was found to involve the production of indoleamine
2,3-dioxygenase (IDO), PGE2, and exosomes.
42
Overall, although analyzing different sample types, i.e., apheresis
products40,42 versus peripheral blood,30,41 and employing different
characterization methods and in vitro analyses, all studies described
above point to the ability of G-CSF to induce heterogeneous
populations of immature and mature neutrophils endowed with
immunomodulating properties in vivo (Fig. 4). To what extent these
cells copurify with HSCs during the apheretic procedures (and how
much the apheresis instrumentation settings may condition this
copurification), how long-lived they are after infusion, and how they
functionally behave after alloHSCT, under an altered immunological
context and concomitant with the administration of immunosup-
pressive drugs, are all currently unknown. With regard to the first
issue, Lv et al.71 evaluated the composition (in terms of MDSC
subtypes) of BM and peripheral blood from 20 HDs before and after
the administration of G-CSF for mobilization, as well as the
composition of the corresponding apheretic grafts. According to
these authors, SSClowCD11b+CD33+CD14+HLA-DR−Lin−CD15dim
CD16− monocytic (M)-, SSChighCD33+CD11bdimCD16−Lin− promye-
locytic (P)-, and SSChighCD11b+CD33dimCD15+HLA-DR−Lin− granu-
locytic (G)- MDSCs were significantly expanded in donor BM and
peripheral blood after G-CSF treatment.71 However, the apheretic
grafts were found to contain lower percentages of G- and P-MDSCs
than mobilized peripheral blood samples.71 By contrast, M-MDSCs
were enriched in the apheretic grafts, indicating that the apheretic
process was able to preferentially retain M-MDSCs compared to P-
and G-MDSCs.71 In partial contrast with these data, αβT-cell- and B
cell-depleted apheresis products from haploidentical donors were
found to contain significantly higher percentages of PMN-MDSCs
(defined as low-density CD45+Lin-HLA-DR−/lowCD33+CD11b+
CD14−CD66b+ cells) than M-MDSCs.42
Other issues that need to be clarified are whether the presence
of immunosuppressive neutrophils in G-CSF-mobilized graft
products may affect outcomes in alloHSCT patients, exerting either
a preventive effect against acute GVHD (aGVHD) or an unwanted
inhibition of GVT. In their evaluation of 62 patients undergoing
haploidentical HSCT from G-CSF-primed BM plus G-CSF-mobilized
PBSCs, Lv et al.71 performed a multivariate analysis that showed an
inverse correlation between the absolute number of P-MDSCs or
M-MDSCs, but not G-MDSCs, infused and the occurrence of grade
II–IV aGVHD and extensive chronic GVHD (cGVHD).
Mature, low-density, immunosuppressive neutrophils with
protective effects against aGVHD have also been described in
mouse models. Accordingly, initial data showed that the low-
density fraction obtained by density gradient centrifugation
of splenocytes from G-CSF-treated mice contains a population of
mostly mature (Gr1+SCA1−) neutrophils, accounting for 20% of
the whole low-density cell fraction (i.e., LDNs).72 LDNs able to
inhibit IFN-γ production by T cells via a mechanism dependent on
hydrogen peroxide were also generated in vitro by treatment of
mouse neutrophils with G-CSF.72 Importantly, in a model of
experimental aGVHD obtained by injecting splenocytes as an
allogeneic T-cell source, the Gr1+ cells present in splenocytes from
G-CSF-treated mice were protective toward aGVHD.72 In fact, the
injection of splenocytes depleted of Gr1+ cells was associated
with the development of aGVHD.72 More recently, Perobelli et al.73
extended these results by demonstrating that the protection
against aGVHD by splenocytes from G-CSF-treated mice relies on
the presence of suppressive IL-10+ LDNs able to induce post
transplant expansion of T regulatory (CD4+CD25+Foxp3+) cells
(Tregs)73. Interestingly, IL-10+ LDNs were characterized by the
authors as activated Ly6C−Ly6G+ cells with elevated phagocytic
capacity, elevated peroxide production, low myeloperoxidase
(MPO) activity, low cytoplasmic granule content, low expression
of MHC class II and costimulatory molecules, and low Arg-1
expression.73 Since the features of these IL-10+ LDNs do not
strictly fit the available description of any known human
neutrophil population, the authors referred to these IL-10+ LDNs
simply as activated and suppressive “G-neutrophils”.73 For a
detailed review of all MDSC types in alloHSCT, either in humans or
in mice, the reader is invited to read the article by D’Aveni et al.74
Taken together, these findings point to complex immunomo-
dulatory roles acquired by neutrophils following G-CSF adminis-
tration to HDs for mobilization. However, further studies are
urgently required to investigate, prospectively and in more
homogeneous cohorts of donors and patients, the presence of
immunomodulating neutrophils in graft products, the extent of
their persistence in recipients after PBSC infusions, and their
relationship with aGVHD occurrence and GVT effects.
NEUTROPHIL IMMUNOPHENOTYPE AND PROPERTIES DURING
IMMUNE RECONSTITUTION IN ALLOHSCT RECIPIENTS
As already mentioned, the HSC engraftment phase of alloHSCT is
followed by the reconstitution of donor-derived innate and
adaptive immune cells. Neutrophils are among the first cells to
reconstitute and thus represent the large majority of circulating
cells, and almost the sole cells of the immune system on which the
patient can rely, in the first weeks after alloHSCT.3,5 However, the
functions and/or features of neutrophil reconstitution after
alloHSCT have been rarely investigated.75 In addition to the old,
classic view of neutrophils as simple phagocytic cells unable to
perform additional biological functions, several impeding factors
(including patient heterogeneity in terms of concomitant clinical
complications and therapies) have hampered the implementation
of studies aimed at defining neutrophil phenotypes and properties
throughout immune reconstitution. Accordingly, peripheral blood
neutrophils of alloHSCT recipients have been traditionally evaluated
only in terms of their numbers by routine blood count analysis to
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assess the achievement of engraftment and the rescue of innate
immunity against infections. Concerning their immunophenotypes,
the little data available in the literature indicate that the large
majority of reconstituting neutrophils consist of terminally differ-
entiated CD10+ and CD16+ cells, expressing CD11b levels similar to
those of HD neutrophils.76,77 Only a few reports have specifically
addressed the issue of immune reconstitution in light of the
most recent advances in neutrophils as heterogeneous cell
populations.18,20 In a study evaluating G- and M-MDSC subsets in
the peripheral blood of 26 patients before conditioning and at six
time points during the first 3 months after alloHSCT, Guan et al.78
identified a population of CD33+CD15+CD66b+ G-MDSCs that, by
days +27 to 29 post-alloHSCT, reached absolute number levels in
the same range of those found in patients during the precondition-
ing period. Interestingly, these cells were functional, as they were
found to suppress CD4+IFN-γ+Th1 cells, as well as to promote the
development of CD4+CD25+Foxp3+ Treg cells in coculture
experiments with CD3/CD28-stimulated third-party CD4+ T cells.78
Consistent with these data, the G-MDSC number at preconditioning
and the ratio of G-MDSCs at days 27–29 to the number at
preconditioning were found to inversely correlate with grades II–IV
aGVHD.78
In a preliminary prospective study analyzing peripheral blood
from 8 HDs and 39 patients at days +21, +42, +60, +90, and
+180 after alloHSCT, we found an increased frequency of LDNs in
the peripheral blood of alloHSCT patients compared to HDs and a
progressive reduction of the immature CD66b+CD10− fraction of
LDNs in patients without GVHD.44 Importantly, consistent with a T-
cell-activating phenotype of immature neutrophils,30 the fre-
quency of CD66b+CD10− LDNs was significantly higher in patients
affected by aGVHD than in patients without this complication.44
Based on the previous two studies,44,78 it seems reasonable to
hypothesize that HSC infusion is followed by the reconstitution of
different populations of neutrophils endowed with immunomo-
dulating properties. Obviously, further research is needed to
establish the real participation of such neutrophil populations in
the pathophysiology of GVHD and/or GVT, as well as to elucidate
their role as potential therapeutic targets.
Contrasting data concerning the maintenance of functional
mature neutrophils during immune reconstitution have been
published.75 In fact, while some authors have reported that the
functions of neutrophils are unaffected, others have described
that they are reduced in the first 1–12 months after alloHSCT,
especially in concomitance with GVHD or other alloHSCT-related
complications. For example, neutrophil chemotaxis has been
reported as either reduced79–81 or unaffected82 relative to that of
cells from HDs. Additionally, phagocytosis has been described to
be either decreased83 or normal.77,81,84,85 Impaired respiratory
burst activity in response to discrete stimuli has been reported to
occur in the first months after alloHSCT by some authors,82,85,86
but not by others.77,87 More recent studies have also pointed to a
reduced capacity of neutrophils from alloHSCT patients to release
NETs in response to PMA88,89 or LPS.76 NETs are extracellular
meshes composed of neutrophil-derived chromosomal DNA,
histones, and granule proteins that provide a scaffold for high
local concentrations of antimicrobial components to kill microbes
extracellularly.90 NET deployment is coupled to plasma membrane
disruption and culminates in a form of cell death called
“NETosis”.91 As with other neutrophil-derived defensive products,
NETs may also be highly toxic to the host, and their release may
contribute to cellular injury and organ dysfunction.92 Once again,
the abovementioned data were obtained from heterogeneous
cohorts of patients in terms of GVHD prophylaxis regimens, which
might explain the conflicting results.
The impact of immunosuppressive drugs on neutrophil func-
tions has been highlighted only recently. Although pharmacolo-
gical agents, such as CSA and tacrolimus/FK-506 (calcineurin
inhibitors, CNIs) and rapamycin [the mammalian target of
rapamycin (mTOR) inhibitor], have been included in aGVHD
prophylaxis schemes with the primary aim of inhibiting T-cell
alloreactivity,10 accumulating evidence points to their interference
with the functionality of innate immune cells. This is the case for
CNIs—part of standard aGVHD prophylaxis regimens—which
inhibit the calcineurin-mediated activation of the transcription
factor known as calcineurin/nuclear factor of activated T cells
(NFAT), as well as the transcription and production of many T-cell-
derived cytokines, including IL-2.93 In vitro evidence has also
indicated that the calcineurin–NFAT pathway activates and
controls important anti-pathogen functions in human and murine
myeloid cells, which, in turn, might be impaired by CNIs.94,95
According to initial studies, in fact, murine neutrophils treated
with CSA in vitro were found to be deficient in Candida albicans
killing activity, similar to neutrophils carrying a conditional
deletion of the calcineurin B gene, thus indicating some
involvement of the calcineurin–NFAT signaling pathway in anti-
fungal actions.94 Notably, the CSA-mediated impairment of fungal
killing was found not to be associated with reductions in
phagocytosis, the production of ROS, the production of nitric
oxide (NO) or MPO degranulation but rather to an as-yet
unidentified impaired killing mechanism.94 By contrast, the
triggering of the calcineurin/NFAT pathway by zymosan (a yeast
component) was found to activate NFAT-dependent genes such
as IL-10, Cox2, Egr1, and Egr2 in murine neutrophils.94 CSA was
also found to downmodulate, in murine neutrophils, the NFAT-
dependent transcription of the nucleotide-binding oligomeriza-
tion domain 1 (nod1) gene, which encodes an intracellular pattern
recognition receptor involved in neutrophil sensing of gram-
negative bacteria and phagocytic response.95 CSA and the
tacrolimus analog ascomycin were subsequently found to dose-
dependently impair the capacity of human neutrophils to release
NETs in vitro in response to CXCL8 or ionomycin96 but not in
response to LPS.97 Very importantly, an ex vivo study comparing
the anti-Aspergillus fumigatus (AF) actions exerted by neutrophils
from alloHSCT patients (at engraftment and 2, 6, and 10 months
after HSC infusion) and from their respective HDs showed a
reduced activity toward AF hyphal growth by patient neutrophils
that persisted until CSA or tacrolimus administration was stopped
or greatly reduced.87 Notably, in the presence of significant
therapeutic CSA or tacrolimus plasma levels, the release of NETs
was the only anti-fungal activity impaired.87 Taken together, these
data indicate that depending on the stimulatory condition, some
anti-pathogen functions of neutrophils may become impaired in
alloHSCT patients by therapeutic concentrations of CNIs.
Recent studies have established an important role for the mTOR
network [composed of mTOR complexes 1 and 2 (mTORC1 and
mTORC2)] in controlling and shaping the effector responses of
innate immunity cells.98 In particular, it has been demonstrated
that mTOR is involved in the control of chemotactic migration,
constitutive mRNA translation and the expression of proinflam-
matory cytokines by human and mouse neutrophils.98 Although
less commonly included in aGVHD prophylaxis schemes than
CNIs,99 rapamycin has been shown to interfere with crucial
neutrophil functions. For instance, in vitro studies have shown that
in human neutrophils, rapamycin inhibits actin polymerization and
consequently interferes with chemotaxis induced by GM-CSF and,
at higher doses, CXCL8100 and phosphatidic acid.101 In addition,
rapamycin can also regulate the release of NETs by human
neutrophils in different manners depending on the stimulus.98
Accordingly, rapamycin was found to inhibit the effect of LPS on
NET release through translational control of HIF-1α, a downstream
regulator of the mTOR pathway and a critical modulator of
antimicrobial defenses.97 By contrast, rapamycin turned out to
accelerate the release rate of NETs by neutrophils stimulated
in vitro with the bacteria-derived peptide formyl-Met-Leu-Phe
(fMLF) via a positive regulation of autophagy.102 Interestingly, NET
release was not observed in a study analyzing neutrophils
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obtained from alloHSCT patients under treatment with CNIs (alone
or in combination with other immunosuppressive agents) and
exposed to rapamycin.88 Finally, rapamycin was also shown to
impair the IL-23-induced production of IL-22 and IL-17 by murine
neutrophils in vitro.103 Therefore, according to these in vitro
observations, human neutrophils may restrain some anti-
pathogen functions when exposed to CNIs or mTOR inhibitors.
Other classes of immunosuppressive agents, including ATG,
methotrexate, mycophenolate mofetil, and post-HSCT cyclopho-
sphamide (which may be used in combination with CNIs or
rapamycin in aGVHD prophylaxis regimens), might impair
neutrophil functions. In addition, the treatment of overt aGVHD
may require the use of additional immunosuppressive agents such
as steroids,10 thus adding further complexity to the evaluation of
neutrophil functionality in the first months after alloHSCT. For
instance, in a prospective study including 51 patients analyzed at
days +30, +90, +180, and +360 after HSCT, Stueheler et al.86
observed that neutrophils tended to have a diminished capacity
to produce ROS toward A. fumigatus in patients with aGVHD under
steroid treatment compared to patients without aGVHD. Although
ex vivo studies are lacking (with the exception of one by Imbert
et al.87), it is conceivable to hypothesize that neutrophils of
alloHSCT patients become deficient in some of their anti-
pathogen functions depending on the pathogen and/or on the
immunosuppressant type and plasma levels.
A further complicating factor in the assessment of neutrophil
competence during immune reconstitution is presented by G-CSF,
which is administered concomitantly to immunosuppressive
agents in selected alloHSCT patients, such as those receiving
CB104 or haploidentical HSCs.105 Based on the evidence that the
administration of ATG delays CD4+ T-cell reconstitution more
severely in patients receiving CB plus G-CSF than in those
receiving BM only, de Koning et al.104 hypothesized that G-CSF
might increase the ATG-mediated phagocytic activity of neutro-
phils toward T cells. Sustaining this hypothesis, neutrophils from
GDs were found to display a strikingly higher capacity to
phagocytize ATG-targeted T cells in vitro than neutrophils from
HDs,104 therefore indicating that, in vivo, G-CSF-activated recon-
stituting neutrophils could be responsible for the delayed T-cell
reconstitution observed after CB infusion.
In light of all the aforementioned findings, it seems reasonable
that researchers involved in studies that analyze neutrophils and
neutrophil populations in the human alloHSCT setting should take
into account the multiple confounding effects deriving from the
concomitant administration of immunosuppressive agents and/or
G-CSF. Therefore, given the higher susceptibility to infections of
patients in the first months following alloHSCT, neutrophil
functionality throughout immune reconstitution should be more
appropriately evaluated in the context of prospective ex vivo
studies obtained from homogeneous groups of patients. This
would allow a better assessment of the extent of the influence of
immunosuppressive agents on neutrophil responses to different
stimuli, as well as their dose-dependent effects.
Finally, functional alterations of neutrophils after alloHSCT may
also depend on genetic variants of pattern recognition receptors
(PPRs) of donor origin.106,107 For instance, extensive studies on
HDs and their corresponding recipients demonstrated that
hyporesponsive Toll-like receptor 4 (TLR4)106 or pentraxin 3107
genetic variants in HSC donor-derived neutrophils might render
alloHSCT patients more susceptible to aspergillosis by affecting
anti-fungal neutrophil activity.
INVOLVEMENT OF NEUTROPHILS IN ALLOHSCT-ASSOCIATED
COMPLICATIONS
AlloHSCT is often associated with early and late noninfectious
(e.g., vascular endothelial syndromes, aGVHD and cGVHD) and
infectious (e.g., CMV reactivation) complications that can threaten
patient survival, aside from primary disease relapse. As briefly
described below, neutrophils have been described to contribute
to the pathogenesis of such complications by virtue of their
different functions, including NET release, ROS production, antigen
presentation and virus internalization and transport (Fig. 5).
Vascular endothelial syndromes
Among early noninfectious complications, vascular endothelial
syndromes represent a range of early life-threatening complica-
tions that often provoke a sudden worsening of patient clinical
condition.108 Transplant-associated thrombotic microangiopathy
(TA-TMA) is one of the most recognized of these entities, together
with capillary leak syndrome, engraftment syndrome, and
idiopathic pneumonia syndrome.108 TA-TMA is caused by a
disseminated platelet clumping in microcirculation and is
characterized by nonimmune hemolytic anemia, thrombocytope-
nia, elevated serum lactate dehydrogenase, schistocytosis and
severe hypertension and proteinuria.109 Consequently, TA-TMA is
associated with a poor prognosis and a high mortality rate owing
to end-organ damage.108,109 The main trigger of TA-TMA is
thought to be damage to the endothelium caused by alloHSCT-
related procedures (e.g., conditioning regimens, CNIs, or anti-
microbial drugs) or their side effects (e.g., infections and
aGVHD).108,109 Importantly, a NET-mediated involvement of
neutrophils in endothelial damage and TA-TMA pathogenesis
has been indicated by recent studies,110–112 which in turn are
based on previous findings obtained in alloHSCT-independent
TMA, such as thrombotic thrombocytopenic purpura and hemo-
lytic uremic syndrome.108,109 However, prior to listing and
discussing the aforementioned studies,110–112 some considera-
tions on NETs/NETosis are necessary. In fact, the involvement of
NETs/NETosis in disease pathogenesis is currently being investi-
gated in a variety of pathologic conditions. Supportive evidence
for NETosis in vivo consists mainly of measuring DNA in blood (or
serum/plasma) or tissue. However, NETs are difficult to track, as
they must be identified by the detection of three separate
molecules that colocalize in their structure (i.e., DNA, histones, and
NE attached to the chromatin). Since there is no doubt that cell-
Fig. 5 Graphic representation of neutrophil effector functions
specifically involved in each of the alloHSCT-associated complica-
tions/conditions, according to published data. NETs neutrophil
extracellular traps, ROS reactive oxygen species, TA-TMA transplant-
associated thrombotic microangiopathy, GVHD graft-versus-host
disease, CMV cytomegalovirus. References for TA-TMA (NETs)110–112;
aGVHD (ROS)122,125; aGVHD (antigen presentation)123; cGVHD
(NETs)129; CMV reactivation (virus transport)140,141
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free DNA can be found in many disorders, entirely independent of
NETs in serum, plasma or tissue, it follows that most of the data
described below must be interpreted with caution. Keeping these
caveats in mind, Arai et al.110 sought to evaluate the predictive
significance of NET serum levels with respect to TA-TMA in a
cohort of 90 adult patients analyzed before conditioning, at
alloHSCT (day 0), and in the fourth week thereafter. These authors
quantified serum NETs as double-stranded (ds) DNAs after having
observed a significant correlation between dsDNA and MPO-DNA
serum levels in a representative group of patients.110 Multivariate
analysis indicated that dsDNA serum levels were predictive for TA-
TMA when either the ratio between day 0 and preconditioning
levels or absolute levels at the fourth week were considered.110 In
addition, immunofluorescence staining of MPO and DNA revealed
NET deposits in the glomeruli of kidney specimens from deceased
TA-TMA patients.110 A subsequent longitudinal study on 103
consecutive alloHSCT pediatric patients (analyzed at days 0, +14,
+30, +60, and +100) aimed at exploring the mechanistic link
between endothelial injury and TA-TMA demonstrated that DNA
levels, measured as a surrogate for NETs, were significantly
increased at day +14 in patients who subsequently developed TA-
TMA.111 Interestingly, neutrophil count and DNA levels were
inversely correlated with concomitantly detected serum levels of
CXCL8, a chemokine that induces neutrophil chemotaxis and NET
release.111 Since day +14 neutrophils were found to display a
downmodulation of CXCR1 and CXCR2 (interpreted as a result of
CXCL8 internalization), the authors hypothesized that CXCL8,
released by damaged endothelium, could induce the release of
NETs by neutrophils and, in turn, the activation of complement
and formation of microthrombi.111 In agreement with this
hypothesis, children undergoing complement-blocking therapy
with eculizumab (a monoclonal antibody targeting C5) for severe
TA-TMA displayed significantly lower DNA serum levels at disease
resolution/therapy discontinuation than at diagnosis and at
4 weeks into treatment.111 Finally, a very recent case–control
study analyzing 30 alloHSCT patients with TA-TMA (n= 10),
aGVHD or cGVHD (n= 10), or without any complication (n= 10)
further clarified that the pathogenesis of TA-TMA relies on
crosstalk among NETs, the complement system and the coagula-
tion cascade.112 In fact, by simultaneously analyzing markers of
NETs (i.e., DNA and MPO-DNA), as well as of complement and
coagulation activation, in serum and/or plasma, the authors found
that TA-TMA patients had an enhanced release of NETs that was
associated with activation of complement and coagulation.112
Notably, serum markers of endothelial damage (i.e., soluble
thrombomodulin and soluble VCAM-1) were detectable not only
in TA-TMA but also in GVHD patients, therefore indicating a
possible overlap between the two pathologies.112 Overall,
although different in terms of design, cohort composition, type
of conditioning, GVHD prophylaxis regimen, time-point assess-
ments, and diagnostic criteria, the studies reported above suggest
neutrophil involvement in TA-TMA pathogenesis through NET
release. This is in agreement with previous in vitro studies
showing that human neutrophils exposed to antineutrophil
cytoplasmic antibodies (ANCAs) activate the alternative comple-
ment pathway via NET release, ultimately damaging the
endothelium through the assembly of membrane attack com-
plexes (C5b-9).113 NETs have also been reported to activate the
coagulation system in both humans and mice. Accordingly,
neutrophils from patients affected by ANCA-associated vasculitis,
a disease characterized by hypercoagulopathy, were shown to
release tissue factor (TF)-expressing NETs.114 In a mouse model,
thrombus-resident neutrophils were also found to contribute to
deep vein thrombosis by activating FXII through NET relase.115
Finally, previous in vivo and in vitro findings have shown that both
human and mouse neutrophils contribute to the thrombotic
process via the release of nucleosomes containing serine
proteases involved in the local proteolytic cleavage of tissue
factor pathway inhibitor,116 the primary inhibitor of the initiation
of the coagulation cascade. On the other hand, no data are
currently available about the involvement of neutrophils in
alloHSCT-related vascular endothelial syndromes other than TA-
TMA. For instance, to the best of our knowledge, there is no
information available about the involvement of NETs in sinusoidal
obstruction syndrome/veno-occlusive disease of the liver, a severe
post-alloHSCT syndrome partially related to endothelial
damage.117 Finally, considering that the release of NETs by
neutrophils was reported as impaired in the same post-alloHSCT
period (the reader is referred to the section “Neutrophil
immunophenotype and properties during immune reconstitution
in alloHSCT recipients” in this review), it remains to be clarified
whether reconstituting neutrophils may actually release NETs in
response to selected disease-associated stimuli.
Acute GVHD (aGVHD)
GVHD is a major complication of alloHSCT and hence a main cause
of post-alloHSCT morbidity and mortality.118 It occurs in acute and
chronic forms, which can be distinguished according to clinical
signs and manifestations that only partially overlap the traditional
chronological classification of acute (before day +100) and
chronic (after day +100) GVHD.119 The acute form of GVHD (i.e.,
aGVHD) remains a significant cause of morbidity and mortality in
alloHSCT recipients.120 It substantially consists of severe inflam-
matory complications resulting from a wide range of immune
mechanisms that donor T cells employ to attack recipient tissues
recognized as “nonself”.120 Indeed, the pathophysiology of aGVHD
has been attributed to a three-phase process consisting of (1)
initial tissue damage from the conditioning regimen, which in turn
leads to (2) activation of host APCs by microbial-associated
molecular patterns (MAMPs)121 and danger-associated molecular
patterns (DAMPs), with activation and proliferation of donor (graft)
T cells, resulting in (3) cytotoxic damage to recipient (host) cells
and release of inflammatory cytokines.120 Interestingly, recent
evidence has indicated that neutrophils may have a role in the
pathogenesis of human and mouse intestinal aGVHD by activating
donor effector T cells, either through the promotion of an
inflammatory microenvironment122 or by presenting host anti-
gens to the T cells in mesenteric LNs (mLNs).123 In fact, in a study
using different alloHSCT mouse models, Schwab et al.122 demon-
strated that, in the conditioning-damaged gastrointestinal tract,
the activated neutrophils of the recipient affect the severity of
aGVHD via the production of ROS, which in addition to reacting
against invading bacteria also damage surrounding/bystander
tissue cells. This latter damage was shown to further activate
neutrophils to elicit a highly inflammatory environment, in turn
promoting T-cell activation and favoring aGVHD development.122
Accordingly, antibody-mediated (anti-Ly6G) or genetically deter-
mined depletion of neutrophils was found to reduce aGVHD
aggressiveness and mortality in the same animal models.122
Importantly, the same authors were able to demonstrate that
neutrophil recruitment occurs upon translocation of intestinal
bacteria into the conditioning-damaged intestinal wall and that
the transfer of TLR2-, TLR3-, TLR4-, TLR7-, or TLR9-deficient
neutrophils into wild-type mice resulted in a less severe aGVHD.122
Consistent with these findings, a prospective collection of
intestinal tissue biopsies from 37 patients undergoing alloHSCT,
with or without aGVHD, made it clear that the severity of intestinal
aGVHD strongly correlates with the number of neutrophils in
GVHD lesions, as well as with anti-nitrotyrosine staining to detect
oxidative damage.122 Overall, these data indicate that total body
irradiation (TBI) and chemotherapy delivered in the context of
conditioning regimes lead to translocation of bacteria into
intestinal tissues, with a consequent recruitment of neutrophils.
Local activation of neutrophils by TLR ligands and neutrophil-
mediated tissue damage by ROS further promote T-cell differ-
entiation into effector T cells, causing aGVHD. In a more recent
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in vivo study, Hulsdunker et al.123 have demonstrated that mouse
neutrophils may also participate in aGVHD pathogenesis by
functioning as APCs. In fact, by using a photoconverter reporter
system, these authors were able to demonstrate that neutrophils,
previously exposed to 405 nm light in the ileum for 7 min after TBI
conditioning, migrated to draining mLNs 1–2 days later.123
Interestingly, neutrophil migration was dependent on the
presence of translocated bacteria (or their components) in mLNs,
as demonstrated by the increased number of bacterial 16S RNA
copies in TBI-treated mice compared with controls, as well as by
the reduced number of neutrophils in the mLNs of antibiotic-
treated mice.123 Interestingly, neutrophils were found to colocalize
with donor-derived T cells in mLNs and therein to present
antigens on major histocompatibility complex-II (MHC-II).123
Accordingly, neutrophil depletion by anti-Ly6 antibodies was
associated with reduced T-cell proliferation in mLNs.123 Notably,
ruxolitinib (the JAK1–JAK2 inhibitor), an effective drug against
GVHD in clinical settings, was shown to interfere with both
neutrophil migration to mLNs and antigen presentation.123
Moreover, ruxolitinib-treated mice were found to display a lower
absolute number of neutrophils in mLNs, with lower MHC-II
expression, than vehicle-treated mice.123 Very recently, the same
group124 has demonstrated reduced aGVHD-related mortality in
mice undergoing active or passive immunization against poly-N-
acetylglucosamine (PNAG), a conserved microbial surface poly-
saccharide that is expressed by various pathogens in murine
aGVHD models. Interestingly, the targeting of PNAG reduced
uncontrolled neutrophil activation in mouse ileum, in turn
favoring the elimination of opsonized bacteria.124 Finally, in
mouse models of aGVHD, allogeneic T-cell-derived GM-CSF was
found to license donor-derived phagocytes, including neutrophils,
to damage host tissues via the release of inflammatory mediators
and ROS.125
Taken together, the studies reported above122,123 confirm the
role of conditioning regimen-induced tissue injury as an early
trigger of aGVHD, resulting in the release of DAMPs and MAMPs. In
this scenario, neutrophils seem to react very efficiently to tissue
damage and bacterial translocation by amplifying damage122 and
promoting allogeneic T-cell activation.123 Despite this convincing
experimental evidence, it remains to be established whether
reducing the intensity of some conditioning regimens may limit
the extent of neutrophil activation in humans. Furthermore, it
would be important to clarify how long patient and graft
neutrophils can survive after conditioning regimens (albeit in an
inflammatory environment caused by the release of proinflam-
matory cytokines126). It would also be important to clarify whether
residual patient and reconstituted donor-derived neutrophils are
able to sustain potent inflammatory activities despite the
administration of immunosuppressive prophylactic agents.
Chronic GVHD (cGVHD)
cGVHD is a major cause of late nonrelapse morbidity and mortality
in alloHSCT patients.127 Clinically, cGVHD is a pleiotropic, multi-
organ syndrome involving tissue inflammation and fibrosis, often
resulting in permanent organ dysfunction.127 The pathophysiol-
ogy of cGVHD involves multiple, distinct interactions among
alloreactive and dysregulated T and B cells and innate immune
populations, including macrophages, DCs and neutrophils, that
culminate in the initiation and propagation of pro-fibrotic
pathways.128 Ocular cGVHD is relatively frequent in alloHSCT
patients.129 Symptoms and signs of ocular cGVHD include ocular
discomfort, tear deficiency with corneal and conjunctival epithe-
liopathy, eyelid disease with Meibomian gland (MG) atrophy,
ocular surface inflammation and cicatrization, and superior limbic
keratoconjunctivitis.129 Neutrophils are hypothesized to be
involved in ocular cGVHD pathogenesis mainly via their release
of NETs. In fact, in a study including 30 patients with ocular
cGVHD, 18 without and 20 HDs, An et al.129 showed by
immunofluorescence staining that NETs were abundant in
mucocellular aggregates and ocular surface washings of patients
affected by ocular cGVHD. Accordingly, MPO- and NE-DNA
complexes and NET-associated proteins [NE, MPO, CXCL8, TNF-α,
brain-derived neurotrophic factor (BDNF), oncostatin M (OSM),
neutrophil gelatinase-associated lipocalin (NGAL), and LIGHT/
TNFSF14] were detected at higher levels in ocular surface
washings from patients with ocular cGVHD than in those from
patients without ocular cGVHD and from HDs.129 Notably, the
same proteins and cytokines (with the exception of TNF-α) were
detected in supernatants from PMA-stimulated human neutro-
phils undergoing NETosis.129 In addition, ocular cGVHD patients
who had an excess of neutrophils over epithelial cells in ocular
surface washings had greater disease severity.129 In cultured
human corneal epithelial cells, the addition of PMA-stimulated
neutrophils as a source of NETs delayed the closure of scratch
wounds and induced epithelial mesenchymal transition.129 In
vitro, NETs also increased the proliferation of cultured human
conjunctival fibroblasts, induced a robust myofibroblast transfor-
mation, caused the contraction of collagen matrices, and
significantly reduced MG cell proliferation and differentiation.129
Importantly, in vivo experiments showed that prolonged applica-
tion of NETs to murine corneas caused epitheliopathy and delayed
epithelial wound healing.129 In addition, disruption of NETs with
heparin diminished all NET-mediated effects in vivo and
in vitro.129 Notably, the same authors were able to identify the
NET-associated enzymes or cytokines most responsible for NET-
mediated pathogenic effects, indicating OSM and LIGHT/TNFSF14
as the main inducers of epitheliopathy and T-cell proliferation and
NGAL as the main inhibitor of MG epithelial cell proliferation and
differentiation.129
As previously stated, neutrophils may exert opposite functions
depending on the stimuli they receive. In keeping with this notion,
recent evidence has shown that neutrophils of cGVHD patients
acquire immunosuppressive properties following extracorporeal
photopheresis (ECP), an immunomodulatory procedure used for
the treatment of steroid-resistant aGVHD or cGVHD.130 ECP
consists of the apheresis of leukocytes from patient whole blood
and their subsequent reinfusion after chemoirradiation with the
photosensitizing agent 8-methoxypsoralene (8-MOP) and UVA
light.130 Although the therapeutic mechanisms of ECP are only
partially known, T cells and DCs have been traditionally regarded
as the main targets.130 However, Franklin et al.131 have recently
demonstrated that neutrophils, accounting for the majority of
leukocytes treated during ECP, undergo some level of apoptosis
and lose their inflammatory properties upon chemoirradiation.
Accordingly, neutrophils obtained from chemoirradiated buffy
coats of cGVHD patients displayed an increased apoptotic rate
after culture for 24 h, while their residual viable fraction showed a
loss of activation markers (CD16, CD54 and, to a lesser extent,
CD11b).131 Upon 24 h of in vitro stimulation with LPS, neutrophils
from chemoirradiated buffy coats of treated patients were found
to reduce the secretion of CXCL8 and CCL4 and increase the
release of Arg-1 compared to nonchemoirradiated neutrophils
from HDs.131 Consistently, compared with neutrophils isolated
from cGVHD patient peripheral blood prior to ECP, neutrophils
isolated 24 h after ECP showed a higher rate of apoptosis and also
lower secretion of CCL4 and increased release of Arg-1 after 24 h
in vitro stimulation with LPS131. Importantly, the neutrophils
isolated 24 h after ECP were able to suppress in vitro the
proliferation of both autologous and heterologous T cells.131 In
agreement with ex vivo findings, in vitro treatment of HD
neutrophils with 8-MOP and UVA accelerated their spontaneous
apoptosis and reduced the expression of activation markers (i.e.,
CD16 and CD54) by the residual viable neutrophils, therefore
reproducing ex vivo data.131 Moreover, following a 24-h in vitro
stimulation with PMA, chemoirradiated neutrophils from HDs
displayed a reduced ROS and NO production capacity compared
Uncovering the multifaceted roles played by neutrophils in allogeneic. . .
C Tecchio and MA Cassatella
9
Cellular & Molecular Immunology _#####################_
to controls, while a 24-h culture with LPS increased their release of
Arg-1.131
Interestingly, subsequent in vitro studies from the same
authors132 demonstrated that 8-MOP- and UVA-treated neutro-
phils are unable to activate autologous DCs, failing to induce their
upregulation of CD80, CD83, and programmed-death ligand 1
(PD-L1) and release of IL-10, TNF-α and IL-12p70. In the same
experimental setting, neutrophils were also found to impair the
LPS-induced and IFNγ-induced activation of DCs.132 Consistently,
DCs previously cultured with chemoirradiated neutrophils showed
a reduced allostimulatory activity in mixed lymphocyte reac-
tion.132 Similar results were observed when culturing chemoirra-
diated neutrophils with other APCs (i.e., monocytes and
macrophages).132 Overall, the two studies described above131,132
indicate that neutrophils of patients undergoing ECP acquire the
capacity to control cGVHD by inhibiting T cells either directly or
indirectly by hampering the activation of APCs.
Rieber et al.43 had previously described in the peripheral blood
of patients affected by aGVHD or cGVHD a population of
functionally active CD33highCD66bhighHLA-DRlowIL-4R+CXCR4+
LDNs/PMN-MDSCs that significantly expanded after ECP treat-
ment. Nonetheless, based on the great prevalence of NDNs over
LDNs in the apheretic leukocytes of patients undergoing ECP,131 it
can be speculated that NDNs, rather than LDNs/PMN-MDSCs,
represent the main effectors of the myeloid-mediated immuno-
suppressive activity of ECP.
Cytomegalovirus (CMV) reactivation
Neutrophils are involved in antiviral immune responses, but the
effects they mediate may be either helpful or detrimental to the
host, depending on the type of viral infection.133 Human CMV
(HCMV) is a β-herpesvirus that establishes a lifelong latent
infection in BM-resident CD34+ cells and CD33+ myeloid
progenitors in infected immunocompetent individuals.134 HCMV
reactivation represents the most frequent opportunistic infection
after alloHSCT134 and a predictor of poor outcomes.135,136 In fact,
recipients of alloHSCT with a positive serology for HCMV are at
increased risk for HCMV reactivation and for early and late
nonrelapse mortality.135,136 Interestingly, the data in the literature
indicate that, although not effective in sustaining a full lytic viral
replication,137,138 HCMV has the capability to exploit and evade
the host immune system in order to ensure its own dissemination
and long-term survival.139,140 In this perspective, neutrophils have
been shown to participate in HCMV dissemination as carriers,
following their recruitment to HCMV-infected sites.141 As such, in
the transendothelial migration assay, human neutrophils were
found to migrate preferentially toward supernatants from HCMV-
infected endothelial cells compared with controls, further expres-
sing the CMV structural protein pp65 upon coculture (i.e., cell-to-
cell contact) with HCMV-infected endothelial cells.141 Although
CXCL8 released by HCMV-infected endothelial cells was initially
indicated as the main neutrophil chemoattractant, subsequent
sequencing studies on HCMV (Toledo strain) identified two viral
genes, namely, UL146 and UL147, with sequence motifs reminis-
cent of human CXCL8.142 In in vitro studies, the product of UL146,
vCXCL-1, acted as a potent neutrophil chemoattractant142 that
was also found to target neutrophils through CXCR1 and CXCR2
binding.143 More recently, an in vivo study conducted in a mouse
model infected with recombinant mouse CMV (MCMV) expressing
HCMV-encoded vCXCL-1 demonstrated that vCXCL-1 is able to
increase MCMV dissemination, thus representing a virulence
factor.140 In addition to their role as carriers, human neutrophils
have been shown to display a remarkable increase in survival in
response to HCMV.144 Accordingly, upon in vitro exposure to the
clinical HCMV isolate Merlin, neutrophils were found to delay their
own apoptosis through the activation of NF-kB and ERK1/2 and
the consequent stabilization of the anti-apoptotic protein MCL-
1.144 In addition, virus-free supernatants from human neutrophils
(but not from monocytes) infected with the same HCMV strain
were found to exert a stronger anti-apoptotic effect toward freshly
isolated neutrophils in vitro compared to controls, likely due to a
higher concentration of pro-survival molecules such as TNF-α, IL-6,
and CXCL8.144 In vitro experiments have also shown that human
neutrophils do not kill latently HCMV-infected monocytes owing
to a suppressed secretion of neutrophil chemoattractants (i.e.,
S100A8/A9) by infected monocytes themeselves.145 However, in
contrast to the supportive role of neutrophils toward CMV, an
in vivo study conducted in a mouse model of primary MCMV
infection reported instead that neutrophils exert TNF-related
apoptosis-inducing ligand (TRAIL)-mediated anti-MCMV activity in
infected tissues upon their CXCL-1-mediated recruitment.146
Despite the accumulating findings regarding potential interac-
tions between neutrophils and CMV, both in human and in mouse
models, much remains to be defined and clarified. In particular, to
the best of our knowledge, no ex vivo studies analyzing ultrapure
neutrophils from alloHSCT patients, with or without HCMV
reactivation, are currently available. These studies would help to
unequivocally define, for instance, the pattern of cytokines and
chemokines expressed and released by neutrophils carrying
HCMV, their phenotypic features or unknown functional
responses. Similarly, no studies have analyzed in detail whether
the clinically known relationship between HCMV reactivation and
GVHD147 may be explained by an increased survival144 and
proinflammatory attitude142 of HCMV-infected neutrophils. In our
opinion, these latter studies are urgent, as neutrophils represent
the first reconstituting cells and are almost the only players in the
immune system in the first months after alloHSCT, when HCMV
usually reactivates and aGVHD occurs.
CONCLUSIONS AND PERSPECTIVES
It is evident that neutrophils participate throughout the entire
alloHSCT procedure, as well as in alloHSCT-related complications
(Fig. 6). In fact, neutrophils are present in graft products, mostly in
G-CSF-mobilized PBSCs, and rapidly reconstitute after HSC
infusion as almost fully competent cells. However, despite data
herein recapitulated, much remains to be explored with regard to
neutrophil functions in the alloHSCT setting. In fact, the role
played by neutrophils in human alloHSCT has been largely
overlooked, especially in light of the multiple, novel biological
activities that have been uncovered in the last years11 (Fig. 1). As
already mentioned in this review, studies are awaited to establish
the effective proportions and the immunomodulating potential-
ities of immature and mature neutrophils copurified in G-CSF-
mobilized HSC products, their precise survival, their possible
response and/or contribution to the cytokine storm, and the type
and amounts of DAMPs/MAMPs they encounter upon infusion in
the recipient, depending on conditioning regimen intensity.
Immune reconstitution is characterized by the rapid restoration
of a normal count of neutrophils with a mature phenotype.
However, the functions of these cells should probably also be
evaluated in terms of the types and plasma levels of the
immunosuppressive drugs used for GVHD prophylaxis and/or
treatment, of the eventual G-CSF administration and of viral
infections. In addition, attention should be paid to the interactions
that neutrophils may establish with the different types of
reconstituting cells, whose compositions (i.e., from innate immune
cells to progressively more competent adaptive immune cells)
may vary over time. Neutrophils may also interact with cells
infused after alloHSCT for therapeutic purposes, such as third-
party MSCs and donor lymphocytes, which are used in the
treatment of GVHD and primary disease relapse, respectively.
Finally, the contributions of neutrophils to many alloHSCT-
associated complications largely remain to be explored.
In conclusion, it is evident that neutrophils may contribute to
alloHSCT outcomes in multiple ways, which are likely to vary
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depending on the characteristics of each patient. Based on the
studies available, it seems reasonable to say that, under alloHSCT
settings, neutrophils are much more than simple phagocytic cells.
Therefore, future studies are awaited to elaborate the still untold
story of neutrophils in alloHSCT and the eventual possibility of
modulating their functions for therapeutic purposes.
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